Effects of an intensive rehabilitation programme on patients with Huntington's disease: a pilot study

Abstract

Objective: To investigate the effects of an intensive, inpatient rehabilitation programme on individuals affected by Huntington's disease.

Design: A pilot study. Within-subjects design.

Setting: Inpatient rehabilitation home of the Italian welfare system.

Subjects: Forty patients, early and middle stage of the disease, were recruited to an intensive, inpatient rehabilitation protocol.

Interventions: The treatment programme included respiratory exercises and speech therapy, physical and occupational therapy and cognitive rehabilitation exercises. The programme involved three-week admission periods of intensive treatment that could be repeated three times a year.

Main measures: A standard clinical assessment was performed at the beginning of each admission using the Zung Depression Scale, Mini-Mental State Examination (MMSE), Barthel Index, Tinetti Scale and Physical Performance Test (PPT). Tinetti and PPT were also used at the end of each admission to assess the outcomes in terms of motor and functional performance.

Results: Each three-week period of treatment resulted in highly significant (P < 0.001) improvements of motor performance and daily life activities. The average increase was 4.7 for Tinetti and 5.21 for PPT scores. No carry-over effect from one admission to the next was apparent but at the same time, no motor decline was detected over two years, indicating that patients maintained a constant level of functional, cognitive as well as motor performance.

Conclusions: Intensive rehabilitation treatments may positively influence the maintenance of functional and motor performance in patients with Huntington's disease.

Get full access to this article

View all access options for this article.

References

Gusella JF , Wexler NS , Conneally PM et al. A polymorphic DNA marker genetically linked to Huntington's disease . Nature 1983; 306: 234—38 .

Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes . Cell 1993; 72: 971—83 .

Bates G. , Harper PS , Jones L. Huntington's disease. Oxford University Press , 2002.

Quarrell O. Huntington's disease: the facts. Oxford University Press , 1999.

Cardoso F. , Seppi K. , Mair KJ , Wenning GK , Poewe W. Seminar on choreas . Lancet Neurol 2006; 5: 589—602 . 6 Rosenblatt A. , Ranen NG , Nance MA , Paulsen JS Physician's guide to the management of Huntington's disease . Huntington's Disease Society of America, 1999.

Hayden MR Huntington's chorea. Springer-Verlag , 1981.

Ross CA , Margolis RL Huntington's disease . Clin Neurosci Res 2001 ; 1: 142—52 .

Garcia Ruiz PJ , Hernandez J. , Cantarero S. , Bartolome M. , Sanchez Bernardos V. , Garcia de Yebenez J. Bradykinesia in Huntington's disease. A prospective, follow-up study . J Neurol 2002; 249: 437—40 . 10 Delval A. , Krystkowiak P. , Blatt JL et al. Role of hypokinesia and bradykinesia in gait disturbances in Huntington's disease: a biomechanical study . J Neurol 2006; 253: 73—80 .

Tian JR , Herdman SJ , Zee DS , Folstein SE Postural control in Huntington's disease (HD) . Acta Otolaryngol Suppl 1991; 481: 333—36 .

10.

Tian JR , Herdman SJ , Zee DS , Folstein SE Postural stability in patients with Huntington's disease . Neurology 1992; 42: 1232—38 .

11.

Rao AK , Quinn L. , Marder KS Reliability of spatiotemporal gait outcome measures in Huntington's disease . Mov Disord 2005; 20: 1033—37 .

12.

Folstein SE The psychopathology of Huntington's disease . Res Publ Assoc Res Nerv Ment Dis 1991; 69: 181—91 .

13.

Folstein SE Huntington's disease: a disorder of families. Johns Hopkins University , 1989.

14.

De Marchi N , Mennella R. Huntington's disease and its association with psychopathology . Harv Rev Psychiatry 2000; 7: 278—89 .

15.

Rosenblatt A. , Leroi I. Neuropsychiatry of Huntington's disease and other basal ganglia disorders . Psychosomatics 2000; 41: 24—30 .

16.

Craufurd D. , Thompson JC , Snowden JS Behavioral changes in Huntington Disease . Neuropsychiatry Neuropsychol Behav Neurol 2001; 14: 219—26 .

17.

Paulsen J. , Ready R. , Hamilton, J. , Mega MS , Cummings JL Neuropsychiatric aspects of Huntington's disease . J Neurol Neurosurg Psychiatry 2001; 71: 310—14 .

18.

Brandt J. Cognitive impairment in Huntington's disease: insights into the neuropsychology of the striatum. In C orkin S ed. Handbook of neuropsychology, Vol 5. E lsevier Science Publishers , 1991.

19.

Lawrence AD , Hodges JR , Rosser A. et al. Evidence for specific cognitive deficits in preclinical Huntington's disease . Brain 1998; 121: 1329—41 . 22 Zakzanis KK The subcortical dementia of Huntington's disease . J Clin Exp Neuropsychol 1998; 20: 565—78 .

20.

Hunt VP , Walker FO Dysphagia in Huntington's disease . J Neurosci Nurs 1989; 21: 92—95 . 24 Kagel MC , Leopold NA Dysphagia in Huntington's disease: a 16-year retrospective . Dysphagia 1992; 7: 106—14 .

21.

Bilney B. , Morris ME , Perry A. Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease: a systematic review . Neurorehabil Neural Repair 2003; 17: 12—24 .

22.

van Dellen A. , Blakemore C. , Deacon R. , York D. , Hannan AJ Delaying the onset of Huntington's in mice . Nature 2000; 404: 721—22 .

23.

van Praag H. , Kempermann G. , Gage FH Neural consequences of environmental enrichment . Nat Rev Neurosci 2000; 1: 191—98 .

24.

Hockly E. , Cordery PM , Woodman B. et al. Environmental enrichment slows disease progression in R6/2 Huntington 's disease mice. Ann Neurol 2002; 51: 235—42 .

25.

Spires TL , Grote HE , Varshney NK et al. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism . J Neurosci 2004; 24: 2270—76 .

26.

Chiu E. Positive caring: remembering the half-full glass. From a videotape of a presentation given at New York University Medical Center in 1989. www.hdsa-wi.org/Caring_for_Individuals_with_Huntington's_Disease.Dr_Chiu.htm

27.

Kirkwood SC , Su JL , Conneally P. , Foroud, T. Progression of symptoms in the early and middle stages of Huntington disease . Arch Neurol 2001; 58: 273—78 .

28.

Shoulson I. , Fahn S. Huntington disease: clinical care and evaluation . Neurology 1979; 29: 1—3 . 33 Shoulson I. , Kulan R. , Rubin A. Assessment of functional capacity in neuro-degenerative movement disorders: Huntington's disease as a prototype . In Munsat T ed. Quantification of neurological deficits . Butterworth Publishers , 1989.

29.

Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency . Mov Disord 1996; 11: 136—42 .

30.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition (DSM-IV). American Psychiatric Association , 1994.

31.

Folstein MF , Folstein SE , McHugh PR Mini-mental state. A practical method for grading the cognitive state of patients for the clinician . J Psychiatr Res 1975; 12: 189—98 .

32.

Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled . Arch Neurol 2006; 63: 991—96 .

33.

Kremer B. , Goldberg P. , Andrew SE et al. A worldwide study of the Huntington's disease mutation. The sensitivity and specificity of measuring CAG repeats . N Engl J Med 1994; 330: 1401—406 .

34.

Lima E. Silva TC , Serra HG , Bertuzzo CS , Lopes-Cendes I. Molecular diagnosis of Huntington disease in Brazilian patients . Arq Neuropsiquiatr 2000; 58: 11—17 . 40 Semaka A. , Creighton S. , Warby S. , Hayden MR Predictive testing for Huntington disease: interpretation and significance of intermediate alleles . Clin Genet 2006; 70: 283—94 .

35.

Levin BC , Richie KL , Jakupciak JP Advances in Huntington's disease diagnostics: development of a standard reference material . Expert Rev Mol Diagn 2006 ; 6: 587—96 .

36.

Gonzalez-Alegre P. , Afifi AK Clinical characteristics of childhood-onset (juvenile) Huntington disease: report of 12 patients and review of the literature .

37.

J Child Neurol 2006; 21: 223—29 .

38.

Li JL , Hayden MR , Warby SC et al. Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23—24: the HD MAPS study. BMC Med Genet 2006; 7: 71 .

39.

Djousse L. , Knowlton B. , Hayden MR et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16 . Neurogenetics 2004 ; 5: 109—14 .

40.

Wexler NS , Lorimer J. , Porter J. et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset . Proc Natl Acad Sci USA 2004; 101: 3498—503 .

41.

Kieburtz K. , MacDonald M. , Shih C. et al. Trinucleotide repeat length and progression of illness in Huntington's disease . J Med Genet 1994; 31: 872—74 .

42.

Rosenblatt A. , Liang KY , Zhou H. et al. The association of CAG repeat length with clinical progression in Huntington disease . Neurology 2006; 66: 1016—20 . 48 Zung WW A self-rating depression scale . Arch Gen Psychiatry 1965; 12: 63—70 .

43.

Mahoney FI , Barthel DW Functional evaluation: the Barthel Index . Md State Med J 1965; 14: 61—65 . 50 Tinetti ME Performance-oriented assessment of mobility problems in elderly patients . J Am Geriatr Soc 1986; 34: 119—26 .

44.

Reuben DB , Siu AL An objective measure of physical function of elderly outpatients. The Physical Performance Test . J Am Geriatr Soc 1990; 38: 1105—12 . 52 Moskowitz CB , Marder K. Palliative care for people with late-stage Huntington's disease . Neurol Clin 2001; 19: 849—65 .

45.

Dixon RA , Hultsch DF Structure and development of metamemory in adulthood . J Gerontol 1983; 38: 682—88 .

46.

Chiu E. Caring for persons with Huntington's disease. Huntington's Disease Society of America , 1991.

47.

Dellefield KS , McDougall GJ Increasing metamemory in older adults . Nurs Res 1996; 45: 284—90 . 56 Paulsen JS Understanding behavioral changes in Huntington's disease. The neuropsychology of Huntington's disease and strategies for intervention . Huntington's Disease Society of America , 2000. 57 Systat 10. Statistics Manuals for SYSTAT for Windows . SPSS Inc. , 2000.

48.

Langbehn DR , Brinkman RR , Falush D. , Paulsen JS , Hayden MR International Huntington's Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length . Clin Genet 2004 ; 65: 267—77 .

49.

Harper PS Huntington's disease. WB Saunders , 1996 .

50.

Nieuwboer A. , De Weerdt W , Dom R. , Truyen M. , Janssens L. , Kamsma Y. The effect of a home physiotherapy program for persons with Parkinson's disease . J Rehabil Med 2001; 33: 266—72 .

51.

Patti F. , Reggio A. , Nicoletti F. , Sellaroli T. , Deinite G., Nicoletti Fr. Effects of rehabilitation therapy on parkinsonian disability and functional independence . J Neurol Rehabil 1996; 10: 223—31 .

52.

Gage H. , Storey L. Rehabilitation for Parkinson's disease: a systematic review of available evidence . Clin Rehabil 2004; 18: 463—82 .

53.

Wade DT , Gage H. , Owen C. , Trend P. , Grossmith C. , Kaye J. Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study . J Neurol Neurosurg Psychiatry 2003; 74: 158—62 .

54.

Deane KH , Ellis-Hill C. , Jones D. et al. Systematic review of paramedical therapies for Parkinson's disease . Mov Disord 2002; 17: 984—91 .

55.

Wheelock VL , Tempkin T. , Marder K. et al. Predictors of nursing home placement in Huntington disease . Neurology 2003; 60: 998—1001 .